Epidemiology of prostate cancer in the Umbria region of Italy: Evidence of opportunistic screening effects

Urology

Volumn 62, Issue 6, 2003, Pages 1040-1044

  La Rosa, Francesco ^a   Stracci, Fabrizio ^a   Minelli, Liliana ^a   Mastrandrea, Vito ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CALCULATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL RATE;

EID: 0345528223     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2003.07.007     Document Type: Article

References (31)

1. Harris R., Lohr K.N. Screening for prostate cancer an update of the evidence for the U.S. Preventive Services Task Force . Ann Intern Med. 137:2002;917-929.
2. Gohagan J.K., Prorok P.C., Kramer B.S., et al. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol. 152:1994;1905-1909.
3. Beemsterboer P.M., de Koning H.J., Kranse R., et al. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer European randomized study of screening for prostate cancer, Rotterdam . J Urol. 164:2000;1216-1220.
4. Cuzick J. Contamination and non-compliance in screening trials. Duffy S.W., Hill C., Estève J. Quantitative Methods for the Evaluation of Cancer Screening. 2001;26-32 Edward Arnold, London.
5. Labrie F., Candas B., Dupont A., et al. Screening decreases prostate cancer death first analysis of the 1988 Quebec prospective randomized controlled trial . Prostate. 38:1999;83-91.
6. Alexander F.E., Prescott R.J. Reply to Labrie et al. Prostate. 40:1999;135-136.
7. Oliver S.E., May M.T., Gunnell D. International trends in prostate-cancer mortality in the "PSA era" Int J Cancer. 92:2001;893-898.
8. Bartsch G., Horninger W., Klocker H., et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 58:2001;417-424.
9. Mettlin C.J., Murphy G.P. Why is the prostate cancer death rate declining in the United States? Cancer. 82:1998;249-251.
10. Coldman A.J., Phillips N., Pickles T.A. Trends in prostate cancer incidence and mortality an analysis of mortality change by screening intensity . Can Med Assoc J. 168:2003;31-35.
11. Lu-Yao G., Albertsen P.C., Stanford J.L., et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 32:2002;740-745.
12. Oliver S.E., Gunnell D., Donovan J.L. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet. 355:2000;1788-1789.
13. Gann P.H., Hennekens C.H., Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 273:1995;289-294.
14. Etzioni R., Penson D.F., Legler J.M., et al. Overdiagnosis due to prostate-specific antigen screening lessons from U.S. prostate cancer incidence trends . J Natl Cancer Inst. 94:2002;981-990.
15. Auvin A., Maattanen L., Stenman U.H., et al. Lead-time in prostate cancer screening (Finland). Cancer Causes Control. 13:2002;279-285.
16. Boccardo F, Bartolozzi C, Cortesi E, et al: Basi scientifiche per la definizione di linee guida in ambito clinico per i tumori. Available at: http://www.progettooncologia.cnr.it/prostata.htm. Accessed March 2003.
17. Smith R.A., Cokkinides V., von Eschenbach A.C., et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin. 52:2002;8-22.
18. Chirpaz E., Colonna M., Menegoz F., et al. Incidence and mortality trends for prostate cancer in 5 French areas from 1982 to 1996. Int J Cancer. 97:2002;372-376.
19. Lu-Yao G.L., Friedman M., Yao S.L. Use of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate specific antigen testing. J Urol. 157:1997;2219-2222.
20. La Rosa F., Stracci F., Petrinelli A.M., et al. Incidence, mortality and long-term survival from prostate cancer in Umbria, Italy, 1978-1994. Eur Urol. 38:2000;388-392.
21. Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death, 9th revision. 1977;WHO, Geneva. vol I.
22. Mastrandrea V, Vitali R, La Rosa F, et al: Incidenza e mortalità per tumori maligni in Umbria (1978-1982). Regione dell'Umbria. Perugia, 1988.
23. Waterhouse J., Muir C., Shanmugaratnam K., et al. Cancer Incidence in Five Continents. 1982;WHO, Lyon. vol IV.
24. Kim H.J., Fay M.P., Feuer E.J., et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 19:2000;335-351.
25. Estève J., Benhamou E., Croasdale M., et al. Relative survival and the estimation of net survival elements for further discussion . Stat Med. 9:1990;529-538.
26. Berrino F, Capocaccia R, Estève J, et al: Survival of cancer patients in Europe: the EUROCARE 2 study. Sc. Publication No. 151, Lyon, IARC, 1999.
27. Zanetti R, Gafà L, Pannelli F, et al (Eds): Cancer in Italy: Incidence Data from Cancer Registries 1993-1998. Roma, Il Pensiero Scientifico, 2002, vol 3.
28. Rosso S., Casella C., Crocetti E., et al. Survival of cancer patients in Italy in the nineties figures from the Cancer Registries . Epidemiol Prev. 25:(suppl):2001;1-375.
29. Russo A., Autelitano M., Bellini A., et al. Estimate of population coverage with the prostate specific antigen (PSA) test to screen for prostate cancer in a metropolitan area of northern Italy. J Med Screen. 9:2002;179-180.
30. Zappa M., Visioli C., Crocetti E., et al. Practice of opportunistic PSA screening in the Florence district. Eur J Cancer Prev. 12:2003;201-204.
31. Crocetti E., Buiatti E., Amorosi A. Prostate cancer population-based survival rates in central Italy . Tumori. 81:1995;81-85.